ReviewNeural regeneration research2012
Neuroprotection and its molecular mechanism following spinal cord injury.
Review in Neural regeneration research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 43 citations in OpenAlex.
- Evaluation of Polyphenol-Rich Lemon Peel Extract Use in a Zebrafish Model of Spinal Cord Injury: Morphology, Repair-Associated Markers, and Inflammatory Profile.International journal of molecular sciences · 2026Article
- Developing an NT3-loaded exosomal biodegradable conductive hydrogel combined with EA for targeted treatment of spinal cord injury.Materials today. Bio · 2025Article
- Mitochondrial Cardiolipin-Targeted Tetrapeptide, SS-31, Exerts Neuroprotective Effects Within In Vitro and In Vivo Models of Spinal Cord Injury.International journal of molecular sciences · 2025Article
- Autonomic dysfunction and hemodynamic management after acute spinal cord injury: blood pressure targets, perfusion strategies, and emerging therapies.Frontiers in neurology · 2025Review
- Fucoidan improving spinal cord injury recovery: Modulating microenvironment and promoting remyelination.CNS neuroscience & therapeutics · 2024Article
- Quantifying injury expansion in the cervical spinal cord with intravital ultrafast contrast-enhanced ultrasound imaging.Experimental neurology · 2024Article
- CCL2 Knockdown Attenuates Inflammatory Response After Spinal Cord Injury Through the PI3K/Akt Signaling Pathway: Bioinformatics Analysis and Experimental Validation.Molecular neurobiology · 2024Article
- Bone marrow mesenchymal stem cells and exercise restore motor function following spinal cord injury by activating PI3K/AKT/mTOR pathway.Neural regeneration research · 2023Article
- Modulating neuroinflammation through molecular, cellular and biomaterial-based approaches to treat spinal cord injury.Bioengineering & translational medicine · 2023Review
- Protective effect of bone morphogenetic protein-7 induced differentiation of bone marrow mesenchymal stem cells in rat with acute spinal cord injury.Functional & integrative genomics · 2023Article
- The role of apoptosis in spinal cord injury: a bibliometric analysis from 1994 to 2023.Frontiers in cellular neuroscience · 2023Article
- An emerging role of inflammasomes in spinal cord injury and spinal cord tumor.Frontiers in immunology · 2023Review
- Restoring mitochondrial cardiolipin homeostasis reduces cell death and promotes recovery after spinal cord injury.Cell death & disease · 2022Article
- Gene-Modified Stem Cells for Spinal Cord Injury: a Promising Better Alternative Therapy.Stem cell reviews and reports · 2022Review
- Article
- Novel Therapeutic Effects in Rat Spinal Cord Injuries: Recovery of the Definitive and Early Spinal Cord Injury by the Administration of Pentadecapeptide BPC 157 Therapy.Current issues in molecular biology · 2022Article
- Gypenoside XVII protects against spinal cord injury in mice by regulating the microRNA‑21‑mediated PTEN/AKT/mTOR pathway.International journal of molecular medicine · 2021Article
- Zinc provides neuroprotection by regulating NLRP3 inflammasome through autophagy and ubiquitination in a spinal contusion injury model.CNS neuroscience & therapeutics · 2021Article
- Targeting axon guidance cues for neural circuit repair after spinal cord injury.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2021Article
- MicroRNA-92a-3p enhances functional recovery and suppresses apoptosis after spinal cord injury via targeting phosphatase and tensin homolog.Bioscience reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Acute spinal cord injury initiates a complex cascade of molecular events termed 'secondary injury', which leads to progressive degeneration ranging from early neuronal apoptosis at the lesion site to delayed degeneration of intact white matter tracts, and, ultimately, expansion of the initial injury. These secondary injury processes include, but are not limited to, inflammation, free radical-induced cell death, glutamate excitotoxicity, phospholipase A2 activation, and induction of extrinsic and intrinsic apoptotic pathways, which are important targets in developing neuroprotective strategies for treatment of spinal cord injury. Recently, a number of studies have shown promising results on neuroprotection and recovery of function in rodent models of spinal cord injury using treatments that target secondary injury processes including inflammation, phospholipase A2 activation, and manipulation of the PTEN-Akt/mTOR signaling pathway. The present review outlines our ongoing research on the molecular mechanisms of neuroprotection in experimental spinal cord injury and briefly summarizes our earlier findings on the therapeutic potential of pharmacological treatments in spinal cord injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.